JP2022550458A - Ｓ１ｐ１受容体に関連する状態を処置する方法 - Google Patents

Ｓ１ｐ１受容体に関連する状態を処置する方法 Download PDF

Info

Publication number
JP2022550458A
JP2022550458A JP2022520471A JP2022520471A JP2022550458A JP 2022550458 A JP2022550458 A JP 2022550458A JP 2022520471 A JP2022520471 A JP 2022520471A JP 2022520471 A JP2022520471 A JP 2022520471A JP 2022550458 A JP2022550458 A JP 2022550458A
Authority
JP
Japan
Prior art keywords
compound
individual
administered
disease
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022520471A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022550458A5 (https=
Inventor
タイ カーティス グエン－クレアリー
リセッテ マリー アセヴェド
Original Assignee
アリーナ ファーマシューティカルズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アリーナ ファーマシューティカルズ， インコーポレイテッド filed Critical アリーナ ファーマシューティカルズ， インコーポレイテッド
Publication of JP2022550458A publication Critical patent/JP2022550458A/ja
Publication of JP2022550458A5 publication Critical patent/JP2022550458A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2022520471A 2019-10-01 2020-09-30 Ｓ１ｐ１受容体に関連する状態を処置する方法 Pending JP2022550458A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962909113P 2019-10-01 2019-10-01
US62/909,113 2019-10-01
PCT/US2020/053642 WO2021067506A1 (en) 2019-10-01 2020-09-30 Methods of treating conditions related to the s1p1 receptor

Publications (2)

Publication Number Publication Date
JP2022550458A true JP2022550458A (ja) 2022-12-01
JP2022550458A5 JP2022550458A5 (https=) 2023-10-10

Family

ID=75337529

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022520471A Pending JP2022550458A (ja) 2019-10-01 2020-09-30 Ｓ１ｐ１受容体に関連する状態を処置する方法

Country Status (12)

Country Link
US (1) US20220347158A1 (https=)
EP (1) EP4037678A4 (https=)
JP (1) JP2022550458A (https=)
KR (1) KR20220074913A (https=)
CN (2) CN115038438A (https=)
AU (1) AU2020360413A1 (https=)
BR (1) BR112022005999A2 (https=)
CA (1) CA3156182A1 (https=)
IL (1) IL291654A (https=)
MX (1) MX2022003982A (https=)
TW (1) TW202114656A (https=)
WO (1) WO2021067506A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240134360A (ko) 2022-01-13 2024-09-09 아레나 파마슈티칼스, 인크. 호르몬 치료와 조합되어 s1p1 수용체-연관된 장애를 치료하는 데 사용하기 위한 에트라시모드

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018504398A (ja) * 2015-01-06 2018-02-15 アリーナ ファーマシューティカルズ， インコーポレイテッド Ｓ１ｐ１受容体に関連する状態の処置方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8580841B2 (en) * 2008-07-23 2013-11-12 Arena Pharmaceuticals, Inc. Substituted 1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid derivatives useful in the treatment of autoimmune and inflammatory disorders
JP5856980B2 (ja) * 2010-01-27 2016-02-10 アリーナ ファーマシューティカルズ， インコーポレイテッド （Ｒ）−２−（７−（４−シクロペンチル−３−（トリフルオロメチル）ベンジルオキシ）−１，２，３，４−テトラヒドロシクロペンタ［ｂ］インドール−３−イル）酢酸およびその塩の調製のためのプロセス
BR112017027656B1 (pt) * 2015-06-22 2023-12-05 Arena Pharmaceuticals, Inc. Hábito cristalino de placa livre de sal de l-arginina de ácido (r)-2-(7-(4- ciclopentil-3-(trifluorometil)benzilóxi)- 1,2,3,4-tetra-hidrociclo-penta[b]indol-3- il)acético, composição farmacêutica que o compreende, seus usos e método de preparação do mesmo
MX2019009843A (es) * 2017-02-16 2020-01-30 Arena Pharm Inc Compuestos y metodos para el tratamiento de la enfermedad inflamatoria intestinal con manifestaciones extraintestinales.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018504398A (ja) * 2015-01-06 2018-02-15 アリーナ ファーマシューティカルズ， インコーポレイテッド Ｓ１ｐ１受容体に関連する状態の処置方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SANDBORN, W.J. ET AL., AM J GASTROENTEROL, vol. 113, JPN6024033983, 2018, pages 327 - 328, ISSN: 0005566167 *

Also Published As

Publication number Publication date
AU2020360413A8 (en) 2022-04-21
WO2021067506A1 (en) 2021-04-08
IL291654A (en) 2022-05-01
BR112022005999A2 (pt) 2022-07-12
US20220347158A1 (en) 2022-11-03
TW202114656A (zh) 2021-04-16
CN119280227A (zh) 2025-01-10
KR20220074913A (ko) 2022-06-03
CN115038438A (zh) 2022-09-09
EP4037678A1 (en) 2022-08-10
EP4037678A4 (en) 2023-11-29
CA3156182A1 (en) 2021-04-08
AU2020360413A1 (en) 2022-04-14
MX2022003982A (es) 2022-07-12

Similar Documents

Publication Publication Date Title
EP3908276B1 (en) Methods of treating conditions related to the s1p1 receptor
WO2022178492A1 (en) Methods of treating ulcerative colitis and crohn's disease
AU2020203867A1 (en) Cenicriviroc for the treatment of fibrosis
JP2017200926A (ja) 第一選択の抗ＴＮＥα療法に失敗したクローン病患者を治療するためのラキニモドの使用
JP2025508406A (ja) Ｃｎｓ関連障害を処置するための神経活性ステロイド
JP2025024035A (ja) Ｓ１ｐ１受容体に関連する状態を治療する方法
Chang et al. Successful treatment of progressive rheumatoid interstitial lung disease with cyclosporine: a case report
AU2015382376A1 (en) Cenicriviroc for the treatment of fibrosis
WO2022099150A1 (en) Methods of treating conditions related to the s1p1 receptor
JP2022550458A (ja) Ｓ１ｐ１受容体に関連する状態を処置する方法
US20250170148A1 (en) Neuroactive steroids for treatment of gastrointestinal diseases or conditions
KR102958419B1 (ko) S1p₁ 수용체와 관련된 병태의 치료 방법
TWI855501B (zh) 治療方法
HK40063670A (en) Methods of treating conditions related to the s1p1 receptor
HK40063670B (en) Methods of treating conditions related to the s1p1 receptor
HK40116740A (zh) 治疗与s1p1受体有关的病况的方法
WO2023214312A1 (en) Methods of treating atopic dermatitis with etrasimod
HK40109901A (zh) 与激素治疗组合的用於治疗s1p1受体相关病症的伊曲莫德
WO2023232884A1 (en) Treatment of ulcerative colitis comprising vidofludimus or a pharmaceutically acceptable salt thereof
AU2023203085A1 (en) Methods of treating conditions related to the S1P1 receptor

Legal Events

Date Code Title Description
RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20230120

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230124

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230928

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230928

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240904

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241120

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241122

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250403